HT
ALLO icon

Headlands Technologies’s Allogene Therapeutics ALLO Stock Holding History

Headlands Technologies’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$427K Sell
205,453
-60,469
-23% -$133K 0.05% 448
2026
Q1 		$649K Buy
265,922
+219,144
+468% +$439K 0.07% 303
2025
Q4 		$64.1K Sell
46,778
-93,183
-67% -$123K 0.01% 645
2025
Q3 		$174K Buy
+139,961
New +$167K 0.01% 547
2024
Q2 		– Sell
-17,396
Closed -$77.8K – 1123
2024
Q1 		$77.8K Buy
+17,396
New +$72.6K 0.02% 604

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Headlands Technologies's ALLO Position: Q2 2026 in Review

Headlands Technologies reduced its Allogene Therapeutics (ALLO) stake by 23% in Q2 2026, selling an estimated $133K and leaving 205,453 shares worth $427K. The position accounts for 0.05% of the portfolio, ranked #448.

Headlands Technologies first reported a position in ALLO in Q1 2024 and has held it in 5 quarters since. The position peaked at $649K in Q1 2026. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Headlands Technologies held 205,453 shares of Allogene Therapeutics worth $427K as of Q2 2026.
  • Headlands Technologies sold 60,469 Allogene Therapeutics shares in Q2 2026, an estimated $133K.
  • Allogene Therapeutics made up 0.05% of Headlands Technologies's portfolio in Q2 2026, its #448 holding.
  • Headlands Technologies first reported a position in Allogene Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • Headlands Technologies's Allogene Therapeutics position peaked at $649K in Q1 2026.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.